Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Luscombe

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Biorxiv : the Preprint Server for Biology|August 6, 2025
Steric control of signaling bias in the immunometabolic receptor GPR84Pinqi Wang, Xuan Zhang, Abdul-Akim Guseinov, et al.
ACS Chemical Neuroscience|August 8, 2018
Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M<sub>1</sub> Positive Allosteric ModulatorsJulie L Engers, Aaron M Bender, Jacob J Kalbfleisch, et al.
ACS Medicinal Chemistry Letters|October 24, 2017
Discovery of VU6005649, a CNS Penetrant mGlu<sub>7/8</sub> Receptor PAM Derived from a Series of Pyrazolo[1,5-<i>a</i>]pyrimidinesMasahito Abe, Mabel Seto, Rocco G Gogliotti, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2021
Discovery of structurally distinct tricyclic M<sub>4</sub> positive allosteric modulator (PAM) chemotypes - Part 2Madeline F Long, Rory A Capstick, Paul K Spearing, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
VU6010608, a Novel mGlu<sub>7</sub> NAM from a Series of <i>N</i>-(2-(1<i>H</i>-1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)benzamidesCarson W Reed, Kevin M McGowan, Paul K Spearing, et al.
ACS Chemical Neuroscience|September 24, 2024
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)Julie L Engers, Logan A Baker, Sichen Chang, et al.
ACS Chemical Neuroscience|December 22, 2016
Diverse Effects on M<sub>1</sub> Signaling and Adverse Effect Liability within a Series of M<sub>1</sub> Ago-PAMsJerri M Rook, Masahito Abe, Hyekyung P Cho, et al.
Bioorganic & Medicinal Chemistry Letters|August 5, 2018
Corrigendum to "Challenges in the development of an M<sub>4</sub> PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides" [Bioorg. Med. Chem. Lett. 27(23) (2017) 5179-5184]James C Tarr, Michael R Wood, Meredith J Noetzel, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2017
Challenges in the development of an M<sub>4</sub> PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amidesJames C Tarr, Michael R Wood, Meredith J Noetzel, et al.
Bioorganic & Medicinal Chemistry Letters|December 13, 2016
Challenges in the development of an M<sub>4</sub> PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogsMichael R Wood, Meredith J Noetzel, Michael S Poslusney, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Biorxiv : the Preprint Server for Biology|August 6, 2025
Steric control of signaling bias in the immunometabolic receptor GPR84Pinqi Wang, Xuan Zhang, Abdul-Akim Guseinov, et al.
ACS Chemical Neuroscience|August 8, 2018
Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M<sub>1</sub> Positive Allosteric ModulatorsJulie L Engers, Aaron M Bender, Jacob J Kalbfleisch, et al.
ACS Medicinal Chemistry Letters|October 24, 2017
Discovery of VU6005649, a CNS Penetrant mGlu<sub>7/8</sub> Receptor PAM Derived from a Series of Pyrazolo[1,5-<i>a</i>]pyrimidinesMasahito Abe, Mabel Seto, Rocco G Gogliotti, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2021
Discovery of structurally distinct tricyclic M<sub>4</sub> positive allosteric modulator (PAM) chemotypes - Part 2Madeline F Long, Rory A Capstick, Paul K Spearing, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
VU6010608, a Novel mGlu<sub>7</sub> NAM from a Series of <i>N</i>-(2-(1<i>H</i>-1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)benzamidesCarson W Reed, Kevin M McGowan, Paul K Spearing, et al.
ACS Chemical Neuroscience|September 24, 2024
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)Julie L Engers, Logan A Baker, Sichen Chang, et al.
ACS Chemical Neuroscience|December 22, 2016
Diverse Effects on M<sub>1</sub> Signaling and Adverse Effect Liability within a Series of M<sub>1</sub> Ago-PAMsJerri M Rook, Masahito Abe, Hyekyung P Cho, et al.
Bioorganic & Medicinal Chemistry Letters|August 5, 2018
Corrigendum to "Challenges in the development of an M<sub>4</sub> PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides" [Bioorg. Med. Chem. Lett. 27(23) (2017) 5179-5184]James C Tarr, Michael R Wood, Meredith J Noetzel, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2017
Challenges in the development of an M<sub>4</sub> PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amidesJames C Tarr, Michael R Wood, Meredith J Noetzel, et al.
Bioorganic & Medicinal Chemistry Letters|December 13, 2016
Challenges in the development of an M<sub>4</sub> PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogsMichael R Wood, Meredith J Noetzel, Michael S Poslusney, et al.
Pageof 4